# Translation

# PATENT COOPERATION TREATY



# **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	1			
Applicant's or agent's file reference P-441WO	FOR FURTHER A	ACTION	See Form PCT/IPEA/416	
International application No.	International filing d	ate (day/month/year)	Priority date (day/month/year)	
PCT/JP2004/000444	20 January 20	04 (20.01.2004)	21 January 2003 (21.01.2003)	
International Patent Classification (IPC) or n A61K 9/20, 47/10, 47/26, 47/32,	ational classification a 47/36, 47/38	nd IPC		
Applicant	NIPPON SHINY	AKU CO., LTD.	·	
This report is the international prelin Authority under Article 35 and trans	ninary examination re mitted to the applicant	port, established by this according to Article 3	International Preliminary Examining 6.	
2. This REPORT consists of a total of	3 sheets	s, including this cover s	sheet.	
3. This report is also accompanied by A				
a. (sent to the applicant and	to the International B	ureau) a total of	shects, as follows:	
and/or sheets cont Administrative Ins	aining rectifications as structions).	uthorized by this Autho	een amended and are the basis of this report prity (see Rule 70.16 and Section 607 of the considers contain an amendment that goes	
beyond the disclos	sure in the internation:	al application as filed,	as indicated in item 4 of Box No. I and the	
	al Bureau only) a, conta dicated in the Suppler	ining a sequence listin	pe and number of electronic carrier(s)) g and/or tables related thereto, in computer b Sequence Listing (see Section 802 of the	
4. This report contains indications relat	ing to the following ite	ems:		
Box No. I Basis of the re	port			
Box No. II Priority				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
Box No. IV Lack of unity of invention				
citations and ex	xplanations supporting	(2) with regard to nove such statement	lty, inventive step or industrial applicability;	
Box No. VI Certain documents cited				
Box No. VII Certain defects in the international application				
Box No. VIII Certain observations on the international application				
Date of submission of the demand		Date of completion o	f this report	
15 July 2004 (15.07.20	004)	06 De	cember 2004 (06.12.2004)	
Name and mailing address of the IPEA/JP		Authorized officer		
Facsimile No.		Telephone No.		

International application No.

PCT/JP2004/000444

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Box No.	1	Basis of the report
1. With other	regard vise in	to the language, this report is based on the international application in the language in which it was filed, unless adicated under this item.
		report is based on translations from the original language into the following language, this language of a translation furnished for the purpose of:
		international search (under Rules 12.3 and 23.1(b))
		publication of the international application (under Rule 12.4)
		international preliminary examination (under Rules 55.2 and/or 55.3)
furnis	hed to	d to the elements of the international application, this report is based on (replacement sheets which have been to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" annexed to this report):
$\boxtimes$	The i	nternational application as originally filed/furnished
	the de	escription:
	pages	
	pages	
	pages	*received by this Authority on
	the cl	aims:
	pages	, as originally filed/furnished
	pages	
	pages	
	pages	* received by this Authority on
	the di	rawings:
	pages	
	pages	
	pages	* received by this Authority on
	a seq	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3.	The a	amendments have resulted in the cancellation of:
		the description, pages
	$\sqcap$	the claims, Nos.
	$\sqcap$	the drawings, sheets/figs
	П	the sequence listing (specify):
	Ħ	any table(s) related to sequence listing (specify):
4.	made	report has been established as if (some of) the amendments annexed to this report and listed below had not been a since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box 270.2(c)).  The description, pages
	Щ	the claims, Nos.
1		the drawings, sheets/figs
1		the sequence listing (specify):
1		any table(s) related to sequence listing (specify):
1		
* If iten	n 4 ap	plies, some or all of those sheets may be marked "superseded."

International application No.

PCT/JP2004/000444

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

tatement			
Novelty (N)	Claims	1-5	YE
	Claims		NC
Inventive step (IS)	Claims		YE
	Claims	1-5	NC
Industrial applicability (IA)	Claims	1-5	YE
	Claims		NC

2. Citations and explanations (Rule 70.7)

Document 1: EP 361874 A2 (TAKEDA CHEMICAL INDUSTRIES, LTD.) April 4, 1990

Based on the description in document 1 cited in the international search report, the inventions of claims 1-5 lack an inventive step.

The inventions of claims 1-5 will now be compared with the invention of document 1.

Document 1 describes core granules wherein a liquid dispersion of low-substituted hydroxypropyl cellulose is sprayed onto the core granules (claim 1). In addition, it lists spherical granules, etc., containing sucrose, etc., as core granules, and it states that the core granules in themselves may be a different active ingredient other than the active ingredient contained in the dispersion (page 2, line 52 to page 3, line 1) and that the core granules may be mixed with other components to produce tablets (page 4, lines 1-6). Furthermore, these core granules and tablets containing the same are to be used for oral administration, and therefore the particle diameter of the granules and thickness of the tablet are essentially the same particle diameter and thickness of the inventions of claims 4 and 5.

Therefore, the two differ because the former concern a tablet melting quickly in the oral cavity, but the latter does not include this specification.

However, document 1 states that the invention described therein has excellent disintegration properties (page 1, lines 37-43). Moreover, in the field of pharmaceuticals it is conventional practice to alter the dosage form as needed and select the optimal dosage form for the drug to be administered. As a result, this examination finds that persons skilled in the art can prepare the invention described in document 1 with excellent disintegration properties as a preparation that disintegrates in the oral cavity, and no particular advantage is provided thereby.